Tag: NASDAQ:MACK

Finance

Biotech Bullish Stocks: Merrimack Pharmaceuticals (NASDAQ:MACK), Sarepta Therapeutics (NASDAQ:SRPT), Northwest Biotherapeutics (NASDAQ:NWBO), Progenics Pharmaceuticals (NASDAQ:PGNX)

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 6.15% in … Continue reading Biotech Bullish Stocks: Merrimack Pharmaceuticals (NASDAQ:MACK), Sarepta Therapeutics (NASDAQ:SRPT), Northwest Biotherapeutics (NASDAQ:NWBO), Progenics Pharmaceuticals (NASDAQ:PGNX)

Mark DeFrance
Finance

Healthcare Unusual Volume: Palatin Technologies (NYSEMKT:PTN), AVEO Pharmaceuticals (NASDAQ:AVEO), Aastrom Biosciences (NASDAQ:ASTM), Merrimack Pharmaceuticals (NASDAQ:MACK)

Palatin Technologies (NYSE:PTN) major shareholder Bvf Partners L. P/Il sold 540,181 shares of Palatin Technologies stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $1.14, for a total transaction of $615,806.34. Palatin Technologies, Inc. (NYSEMKT:PTN) stock performance was 17.07% in last session and finished the day at $1.44. Traded volume was 3.33 million shares in the last … Continue reading Healthcare Unusual Volume: Palatin Technologies (NYSEMKT:PTN), AVEO Pharmaceuticals (NASDAQ:AVEO), Aastrom Biosciences (NASDAQ:ASTM), Merrimack Pharmaceuticals (NASDAQ:MACK)

Jayne Crisman
BioTech

Biotech Most Volatile: CytRx Corporation (NASDAQ:CYTR), Merrimack Pharmaceuticals (NASDAQ:MACK), CEL-SCI Corporation (NYSEMKT:CVM), IGI Laboratories (NYSEMKT:IG)

CytRx Corporation (NASDAQ:CYTR) on Mar. 5 reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -4.14% in last session and finished the day at $5.10. Traded volume was 3,687,994 million shares in the last session and the average volume of the … Continue reading Biotech Most Volatile: CytRx Corporation (NASDAQ:CYTR), Merrimack Pharmaceuticals (NASDAQ:MACK), CEL-SCI Corporation (NYSEMKT:CVM), IGI Laboratories (NYSEMKT:IG)

Mark DeFrance
BioTech

Biotech Top Gainers: Northwest Biotherapeutics (NASDAQ:NWBO), Alexion Pharmaceuticals (NASDAQ:ALXN), Merrimack Pharmaceuticals (NASDAQ:MACK), Enzon Pharmaceuticals (NASDAQ:ENZN)

German health regulators have granted Northwest Biotherapeutics Inc (NASDAQ:NWBO) special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small US biotechnology company has not yet completed its late-stage trial of the immunotherapy. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 29.55% in last session and finished the day at $7.85. Traded volume was 6,155,092 million shares in the last … Continue reading Biotech Top Gainers: Northwest Biotherapeutics (NASDAQ:NWBO), Alexion Pharmaceuticals (NASDAQ:ALXN), Merrimack Pharmaceuticals (NASDAQ:MACK), Enzon Pharmaceuticals (NASDAQ:ENZN)

Richard Atkins
Finance

Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

On Jan 22, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack’s Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue … Continue reading Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

Chris Lewis